MXPA06006659A

MXPA06006659A - Composicion y metodos para modular la actividad del sistema nervioso central.

Composicion y metodos para modular la actividad del sistema nervioso central.

Info

Publication number: MXPA06006659A
Authority: MX; Mexico
Prior art keywords: agonist; disorder; mammal; substituted; polypeptide
Prior art date: 2003-12-19

Application number

MXPA06006659A

Other languages

English (en)

Spanish (es)

Inventor

Lee L Rubin

Original Assignee

Curis Inc

Priority date

2003-12-19

Filing date

2004-12-15

Publication date

2006-08-31

2004-12-15 Application filed by Curis Inc filed Critical Curis Inc

2006-08-31 Publication of MXPA06006659A publication Critical patent/MXPA06006659A/es

Links

238000000034 method Methods 0.000 title claims abstract description 184
239000000203 mixture Substances 0.000 title claims abstract description 71
230000000694 effects Effects 0.000 title description 56
239000000556 agonist Substances 0.000 claims abstract description 99
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 76
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 42
238000011282 treatment Methods 0.000 claims abstract description 42
208000024891 symptom Diseases 0.000 claims abstract description 37
210000003169 central nervous system Anatomy 0.000 claims abstract description 33
230000003920 cognitive function Effects 0.000 claims abstract description 23
230000006870 function Effects 0.000 claims abstract description 23
230000003542 behavioural effect Effects 0.000 claims abstract description 21
230000006386 memory function Effects 0.000 claims abstract description 13
208000027534 Emotional disease Diseases 0.000 claims abstract description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 202
102000004196 processed proteins & peptides Human genes 0.000 claims description 184
229920001184 polypeptide Polymers 0.000 claims description 166
108090000623 proteins and genes Proteins 0.000 claims description 151
230000009368 gene silencing by RNA Effects 0.000 claims description 61
239000003795 chemical substances by application Substances 0.000 claims description 58
230000015654 memory Effects 0.000 claims description 58
150000007523 nucleic acids Chemical class 0.000 claims description 56
208000035475 disorder Diseases 0.000 claims description 53
102000039446 nucleic acids Human genes 0.000 claims description 51
108020004707 nucleic acids Proteins 0.000 claims description 51
206010012289 Dementia Diseases 0.000 claims description 46
125000003275 alpha amino acid group Chemical group 0.000 claims description 43
239000013598 vector Substances 0.000 claims description 43
239000002773 nucleotide Substances 0.000 claims description 42
125000003729 nucleotide group Chemical group 0.000 claims description 42
230000008410 smoothened signaling pathway Effects 0.000 claims description 41
108020004459 Small interfering RNA Proteins 0.000 claims description 37
150000001875 compounds Chemical class 0.000 claims description 34
241000124008 Mammalia Species 0.000 claims description 29
238000009472 formulation Methods 0.000 claims description 29
108010069873 Patched Receptors Proteins 0.000 claims description 27
239000012634 fragment Substances 0.000 claims description 26
230000011664 signaling Effects 0.000 claims description 26
102000000017 Patched Receptors Human genes 0.000 claims description 25
238000002360 preparation method Methods 0.000 claims description 23
230000002996 emotional effect Effects 0.000 claims description 20
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 19
241001465754 Metazoa Species 0.000 claims description 19
208000019901 Anxiety disease Diseases 0.000 claims description 17
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 17
208000020401 Depressive disease Diseases 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 17
208000011580 syndromic disease Diseases 0.000 claims description 17
108020003175 receptors Proteins 0.000 claims description 16
102000005962 receptors Human genes 0.000 claims description 16
239000003112 inhibitor Substances 0.000 claims description 15
230000007812 deficiency Effects 0.000 claims description 14
238000011161 development Methods 0.000 claims description 14
208000010877 cognitive disease Diseases 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 13
238000011321 prophylaxis Methods 0.000 claims description 13
238000010276 construction Methods 0.000 claims description 12
230000036541 health Effects 0.000 claims description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
230000001976 improved effect Effects 0.000 claims description 11
230000008901 benefit Effects 0.000 claims description 8
230000037361 pathway Effects 0.000 claims description 8
230000001225 therapeutic effect Effects 0.000 claims description 8
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
230000002159 abnormal effect Effects 0.000 claims description 7
230000006866 deterioration Effects 0.000 claims description 7
238000009826 distribution Methods 0.000 claims description 7
239000000463 material Substances 0.000 claims description 7
206010041250 Social phobia Diseases 0.000 claims description 6
239000011780 sodium chloride Substances 0.000 claims description 6
231100000419 toxicity Toxicity 0.000 claims description 6
230000001988 toxicity Effects 0.000 claims description 6
230000001149 cognitive effect Effects 0.000 claims description 5
208000019906 panic disease Diseases 0.000 claims description 5
230000001718 repressive effect Effects 0.000 claims description 5
230000002825 dopamine reuptake Effects 0.000 claims description 4
230000036961 partial effect Effects 0.000 claims description 4
102000040430 polynucleotide Human genes 0.000 claims description 4
108091033319 polynucleotide Proteins 0.000 claims description 4
239000002157 polynucleotide Substances 0.000 claims description 4
208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
238000005406 washing Methods 0.000 claims description 4
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
230000006993 memory improvement Effects 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
208000019899 phobic disease Diseases 0.000 claims description 3
206010034912 Phobia Diseases 0.000 claims description 2
231100000876 cognitive deterioration Toxicity 0.000 claims description 2
230000001747 exhibiting effect Effects 0.000 claims description 2
230000003993 interaction Effects 0.000 claims description 2
239000001509 sodium citrate Substances 0.000 claims description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
108091030071 RNAI Proteins 0.000 claims 9
239000000306 component Substances 0.000 claims 3
102000013380 Smoothened Receptor Human genes 0.000 claims 2
108010090739 Smoothened Receptor Proteins 0.000 claims 2
239000005426 pharmaceutical component Substances 0.000 claims 2
206010000117 Abnormal behaviour Diseases 0.000 claims 1
208000035415 Reinfection Diseases 0.000 claims 1
230000004766 neurogenesis Effects 0.000 abstract description 18
210000002569 neuron Anatomy 0.000 abstract description 18
208000000044 Amnesia Diseases 0.000 abstract description 16
230000004069 differentiation Effects 0.000 abstract description 14
230000006735 deficit Effects 0.000 abstract description 10
230000005062 synaptic transmission Effects 0.000 abstract description 5
208000026139 Memory disease Diseases 0.000 abstract description 3
230000006984 memory degeneration Effects 0.000 abstract description 3
208000023060 memory loss Diseases 0.000 abstract description 3
230000009459 hedgehog signaling Effects 0.000 abstract description 2
230000002708 enhancing effect Effects 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 description 147
125000001072 heteroaryl group Chemical group 0.000 description 130
125000003118 aryl group Chemical group 0.000 description 127
-1 indalpin Chemical compound 0.000 description 115
125000003342 alkenyl group Chemical group 0.000 description 97
210000004027 cell Anatomy 0.000 description 87
102000004169 proteins and genes Human genes 0.000 description 73
235000018102 proteins Nutrition 0.000 description 65
108091032973 (ribonucleotides)n+m Proteins 0.000 description 57
125000000623 heterocyclic group Chemical group 0.000 description 53
125000001424 substituent group Chemical group 0.000 description 47
230000014509 gene expression Effects 0.000 description 41
229910052736 halogen Inorganic materials 0.000 description 37
150000002367 halogens Chemical class 0.000 description 37
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 34
125000000304 alkynyl group Chemical group 0.000 description 32
241000282414 Homo sapiens Species 0.000 description 31
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 31
102000040650 (ribonucleotides)n+m Human genes 0.000 description 30
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 30
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 30
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 30
125000002619 bicyclic group Chemical group 0.000 description 29
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 28
125000003710 aryl alkyl group Chemical group 0.000 description 28
241000251539 Vertebrata <Metazoa> Species 0.000 description 26
235000001014 amino acid Nutrition 0.000 description 26
125000004093 cyano group Chemical group *C#N 0.000 description 26
125000005647 linker group Chemical group 0.000 description 26
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 25
229940024606 amino acid Drugs 0.000 description 25
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 25
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 24
125000004429 atom Chemical group 0.000 description 24
125000000753 cycloalkyl group Chemical group 0.000 description 24
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 24
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 23
230000002068 genetic effect Effects 0.000 description 23
239000004055 small Interfering RNA Substances 0.000 description 23
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 22
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 22
150000001413 amino acids Chemical class 0.000 description 21
201000010099 disease Diseases 0.000 description 21
HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical class C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 20
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 20
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 20
108091028043 Nucleic acid sequence Proteins 0.000 description 20
150000001299 aldehydes Chemical class 0.000 description 20
150000005347 biaryls Chemical group 0.000 description 20
239000003431 cross linking reagent Substances 0.000 description 20
150000002576 ketones Chemical class 0.000 description 20
239000013612 plasmid Substances 0.000 description 20
229910052717 sulfur Inorganic materials 0.000 description 20
229910052739 hydrogen Inorganic materials 0.000 description 19
239000001257 hydrogen Substances 0.000 description 19
208000019116 sleep disease Diseases 0.000 description 19
238000006467 substitution reaction Methods 0.000 description 19
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 18
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 18
125000004435 hydrogen atom Chemical class [H]* 0.000 description 18
238000001727 in vivo Methods 0.000 description 18
125000003367 polycyclic group Chemical group 0.000 description 18
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 18
108020004414 DNA Proteins 0.000 description 17
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 17
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 17
108020001507 fusion proteins Proteins 0.000 description 17
102000037865 fusion proteins Human genes 0.000 description 17
150000003335 secondary amines Chemical group 0.000 description 17
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 17
125000003396 thiol group Chemical group [H]S* 0.000 description 17
230000003612 virological effect Effects 0.000 description 17
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 16
125000004442 acylamino group Chemical group 0.000 description 16
239000000935 antidepressant agent Substances 0.000 description 16
229940005513 antidepressants Drugs 0.000 description 16
238000006243 chemical reaction Methods 0.000 description 16
230000001537 neural effect Effects 0.000 description 16
229910052757 nitrogen Inorganic materials 0.000 description 16
150000003141 primary amines Chemical class 0.000 description 16
150000003462 sulfoxides Chemical class 0.000 description 16
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 15
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 15
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 15
230000001105 regulatory effect Effects 0.000 description 15
230000007958 sleep Effects 0.000 description 15
238000012360 testing method Methods 0.000 description 15
125000001544 thienyl group Chemical group 0.000 description 15
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 14
210000004556 brain Anatomy 0.000 description 14
238000001476 gene delivery Methods 0.000 description 14
125000004475 heteroaralkyl group Chemical group 0.000 description 14
125000005842 heteroatom Chemical group 0.000 description 14
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 14
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 13
150000001412 amines Chemical class 0.000 description 13
229910052760 oxygen Inorganic materials 0.000 description 13
241001430294 unidentified retrovirus Species 0.000 description 13
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 12
241000700605 Viruses Species 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 12
230000006986 amnesia Effects 0.000 description 12
125000005605 benzo group Chemical group 0.000 description 12
230000018109 developmental process Effects 0.000 description 12
229940079593 drug Drugs 0.000 description 12
230000001177 retroviral effect Effects 0.000 description 12
208000020685 sleep-wake disease Diseases 0.000 description 12
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 11
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 11
230000004913 activation Effects 0.000 description 11
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 11
238000001415 gene therapy Methods 0.000 description 11
230000004044 response Effects 0.000 description 11
210000000130 stem cell Anatomy 0.000 description 11
208000020925 Bipolar disease Diseases 0.000 description 10
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 10
108060003951 Immunoglobulin Proteins 0.000 description 10
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 10
208000016285 Movement disease Diseases 0.000 description 10
230000004520 agglutination Effects 0.000 description 10
230000004075 alteration Effects 0.000 description 10
125000003277 amino group Chemical group 0.000 description 10
239000000427 antigen Substances 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
101150102226 hh gene Proteins 0.000 description 10
102000018358 immunoglobulin Human genes 0.000 description 10
208000015181 infectious disease Diseases 0.000 description 10
230000000926 neurological effect Effects 0.000 description 10
125000004076 pyridyl group Chemical group 0.000 description 10
239000000126 substance Substances 0.000 description 10
238000007792 addition Methods 0.000 description 9
125000004414 alkyl thio group Chemical group 0.000 description 9
230000004071 biological effect Effects 0.000 description 9
125000002837 carbocyclic group Chemical group 0.000 description 9
125000004452 carbocyclyl group Chemical group 0.000 description 9
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
238000003745 diagnosis Methods 0.000 description 9
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
210000001320 hippocampus Anatomy 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
206010022437 insomnia Diseases 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
230000000750 progressive effect Effects 0.000 description 9
238000000746 purification Methods 0.000 description 9
150000003512 tertiary amines Chemical group 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
239000013603 viral vector Substances 0.000 description 9
108091026890 Coding region Proteins 0.000 description 8
244000060234 Gmelina philippensis Species 0.000 description 8
208000023105 Huntington disease Diseases 0.000 description 8
206010026749 Mania Diseases 0.000 description 8
208000005793 Restless legs syndrome Diseases 0.000 description 8
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
125000004970 halomethyl group Chemical group 0.000 description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 8
238000013508 migration Methods 0.000 description 8
230000035772 mutation Effects 0.000 description 8
239000002245 particle Substances 0.000 description 8
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 8
239000011593 sulfur Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
230000017105 transposition Effects 0.000 description 8
241000701161 unidentified adenovirus Species 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 7
241000282412 Homo Species 0.000 description 7
241000725303 Human immunodeficiency virus Species 0.000 description 7
208000018737 Parkinson disease Diseases 0.000 description 7
208000028017 Psychotic disease Diseases 0.000 description 7
125000003545 alkoxy group Chemical group 0.000 description 7
239000002249 anxiolytic agent Substances 0.000 description 7
125000004122 cyclic group Chemical group 0.000 description 7
210000003527 eukaryotic cell Anatomy 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
239000002502 liposome Substances 0.000 description 7
230000007787 long-term memory Effects 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
230000005012 migration Effects 0.000 description 7
239000002858 neurotransmitter agent Substances 0.000 description 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
239000001301 oxygen Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
125000000714 pyrimidinyl group Chemical group 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000004936 stimulating effect Effects 0.000 description 7
125000000335 thiazolyl group Chemical group 0.000 description 7
208000012661 Dyskinesia Diseases 0.000 description 6
206010013980 Dyssomnias Diseases 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
208000006011 Stroke Diseases 0.000 description 6
230000001430 anti-depressive effect Effects 0.000 description 6
230000000692 anti-sense effect Effects 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
230000006399 behavior Effects 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
230000015556 catabolic process Effects 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
239000003184 complementary RNA Substances 0.000 description 6
230000007547 defect Effects 0.000 description 6
230000007850 degeneration Effects 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
238000013461 design Methods 0.000 description 6
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
230000002209 hydrophobic effect Effects 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 6
230000010076 replication Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
150000003923 2,5-pyrrolediones Chemical class 0.000 description 5
206010003694 Atrophy Diseases 0.000 description 5
208000014644 Brain disease Diseases 0.000 description 5
208000019888 Circadian rhythm sleep disease Diseases 0.000 description 5
241000252212 Danio rerio Species 0.000 description 5
201000011240 Frontotemporal dementia Diseases 0.000 description 5
208000015814 Intrinsic Sleep disease Diseases 0.000 description 5
101710181812 Methionine aminopeptidase Proteins 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
101710163270 Nuclease Proteins 0.000 description 5
208000000609 Pick Disease of the Brain Diseases 0.000 description 5
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
230000009102 absorption Effects 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000003213 activating effect Effects 0.000 description 5
230000036506 anxiety Effects 0.000 description 5
230000000949 anxiolytic effect Effects 0.000 description 5
201000007201 aphasia Diseases 0.000 description 5
230000037444 atrophy Effects 0.000 description 5
125000005884 carbocyclylalkyl group Chemical group 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
230000008859 change Effects 0.000 description 5
230000001054 cortical effect Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
230000002950 deficient Effects 0.000 description 5
230000000994 depressogenic effect Effects 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
210000003414 extremity Anatomy 0.000 description 5
125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
229930195733 hydrocarbon Natural products 0.000 description 5
150000002430 hydrocarbons Chemical class 0.000 description 5
230000006872 improvement Effects 0.000 description 5
208000014674 injury Diseases 0.000 description 5
208000024714 major depressive disease Diseases 0.000 description 5
206010027175 memory impairment Diseases 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
230000003278 mimic effect Effects 0.000 description 5
210000004898 n-terminal fragment Anatomy 0.000 description 5
230000007514 neuronal growth Effects 0.000 description 5
150000002894 organic compounds Chemical class 0.000 description 5
238000004806 packaging method and process Methods 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
238000012545 processing Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
230000009467 reduction Effects 0.000 description 5
150000003384 small molecules Chemical class 0.000 description 5
230000035882 stress Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
206010065040 AIDS dementia complex Diseases 0.000 description 4
108700028369 Alleles Proteins 0.000 description 4
208000031091 Amnestic disease Diseases 0.000 description 4
208000020706 Autistic disease Diseases 0.000 description 4
206010008748 Chorea Diseases 0.000 description 4
241000702421 Dependoparvovirus Species 0.000 description 4
229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
241000287828 Gallus gallus Species 0.000 description 4
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
208000036626 Mental retardation Diseases 0.000 description 4
208000019022 Mood disease Diseases 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
208000012902 Nervous system disease Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
108010039918 Polylysine Proteins 0.000 description 4
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
208000010340 Sleep Deprivation Diseases 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
108700019146 Transgenes Proteins 0.000 description 4
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
235000013330 chicken meat Nutrition 0.000 description 4
229940126523 co-drug Drugs 0.000 description 4
230000007278 cognition impairment Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
239000000221 dopamine uptake inhibitor Substances 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
125000001153 fluoro group Chemical group F* 0.000 description 4
125000002541 furyl group Chemical group 0.000 description 4
230000004927 fusion Effects 0.000 description 4
125000004969 haloethyl group Chemical group 0.000 description 4
230000002989 hypothyroidism Effects 0.000 description 4
208000003532 hypothyroidism Diseases 0.000 description 4
230000008449 language Effects 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000003340 mental effect Effects 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 4
229920000656 polylysine Polymers 0.000 description 4
230000002265 prevention Effects 0.000 description 4
208000020016 psychiatric disease Diseases 0.000 description 4
230000000306 recurrent effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
238000012552 review Methods 0.000 description 4
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
238000007363 ring formation reaction Methods 0.000 description 4
230000011218 segmentation Effects 0.000 description 4
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
201000002859 sleep apnea Diseases 0.000 description 4
RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical class [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 4
241000894007 species Species 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
238000003860 storage Methods 0.000 description 4
210000004281 subthalamic nucleus Anatomy 0.000 description 4
230000000946 synaptic effect Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
238000010361 transduction Methods 0.000 description 4
230000026683 transduction Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
ODVRLSOMTXGTMX-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrole-2,5-dione Chemical compound NCCN1C(=O)C=CC1=O ODVRLSOMTXGTMX-UHFFFAOYSA-N 0.000 description 3
ADEORFBTPGKHRP-UHFFFAOYSA-N 1-[7-(dimethylamino)-4-methyl-2-oxochromen-3-yl]pyrrole-2,5-dione Chemical compound O=C1OC2=CC(N(C)C)=CC=C2C(C)=C1N1C(=O)C=CC1=O ADEORFBTPGKHRP-UHFFFAOYSA-N 0.000 description 3
QMGUOJYZJKLOLH-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(CCCN(C)C)C=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O QMGUOJYZJKLOLH-UHFFFAOYSA-N 0.000 description 3
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
208000006888 Agnosia Diseases 0.000 description 3
241001047040 Agnosia Species 0.000 description 3
108020005544 Antisense RNA Proteins 0.000 description 3
206010003062 Apraxia Diseases 0.000 description 3
206010003591 Ataxia Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
208000011990 Corticobasal Degeneration Diseases 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
201000010374 Down Syndrome Diseases 0.000 description 3
108700018846 Drosophila hh Proteins 0.000 description 3
208000014094 Dystonic disease Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010017577 Gait disturbance Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
108090000031 Hedgehog Proteins Proteins 0.000 description 3
102000003693 Hedgehog Proteins Human genes 0.000 description 3
102100034353 Integrase Human genes 0.000 description 3
208000001089 Multiple system atrophy Diseases 0.000 description 3
208000002033 Myoclonus Diseases 0.000 description 3
125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
108010025020 Nerve Growth Factor Proteins 0.000 description 3
208000025966 Neurological disease Diseases 0.000 description 3
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
101100463797 Rattus norvegicus Pgrmc1 gene Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000016571 aggressive behavior Effects 0.000 description 3
125000003368 amide group Chemical group 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000000561 anti-psychotic effect Effects 0.000 description 3
235000019789 appetite Nutrition 0.000 description 3
230000036528 appetite Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
210000004227 basal ganglia Anatomy 0.000 description 3
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000000133 brain stem Anatomy 0.000 description 3
238000004422 calculation algorithm Methods 0.000 description 3
210000001638 cerebellum Anatomy 0.000 description 3
210000003710 cerebral cortex Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
BSCOYGIDBGKPIX-UHFFFAOYSA-N diazenylphosphonic acid Chemical compound OP(O)(=O)N=N BSCOYGIDBGKPIX-UHFFFAOYSA-N 0.000 description 3
229960003638 dopamine Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
208000024732 dysthymic disease Diseases 0.000 description 3
208000010118 dystonia Diseases 0.000 description 3
230000013020 embryo development Effects 0.000 description 3
108010078428 env Gene Products Proteins 0.000 description 3
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
229960002464 fluoxetine Drugs 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
239000004220 glutamic acid Substances 0.000 description 3
229960002989 glutamic acid Drugs 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
208000013403 hyperactivity Diseases 0.000 description 3
125000002883 imidazolyl group Chemical group 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000003933 intellectual function Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
150000002634 lipophilic molecules Chemical class 0.000 description 3
230000007774 longterm Effects 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
230000036407 pain Effects 0.000 description 3
125000005936 piperidyl group Chemical group 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
201000002212 progressive supranuclear palsy Diseases 0.000 description 3
210000001236 prokaryotic cell Anatomy 0.000 description 3
125000000168 pyrrolyl group Chemical group 0.000 description 3
239000011535 reaction buffer Substances 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
238000011084 recovery Methods 0.000 description 3
125000006413 ring segment Chemical group 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
201000000980 schizophrenia Diseases 0.000 description 3
230000007017 scission Effects 0.000 description 3
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
208000022925 sleep disturbance Diseases 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
201000009032 substance abuse Diseases 0.000 description 3
125000000547 substituted alkyl group Chemical group 0.000 description 3
230000001629 suppression Effects 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
210000003478 temporal lobe Anatomy 0.000 description 3
150000007970 thio esters Chemical class 0.000 description 3
239000005495 thyroid hormone Substances 0.000 description 3
229940036555 thyroid hormone Drugs 0.000 description 3
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 2
GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 2
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
AYDAHOIUHVUJHQ-UHFFFAOYSA-N 1-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)pyrrole-2,5-dione Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2N1C(=O)C=CC1=O AYDAHOIUHVUJHQ-UHFFFAOYSA-N 0.000 description 2
AHLAQJXELUHIEW-UHFFFAOYSA-N 1-(5-aminopentyl)pyrrole-2,5-dione Chemical compound NCCCCCN1C(=O)C=CC1=O AHLAQJXELUHIEW-UHFFFAOYSA-N 0.000 description 2
AASYSXRGODIQGY-UHFFFAOYSA-N 1-[1-(2,5-dioxopyrrol-1-yl)hexyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(CCCCC)N1C(=O)C=CC1=O AASYSXRGODIQGY-UHFFFAOYSA-N 0.000 description 2
GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical class ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 2
YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
239000013607 AAV vector Substances 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 2
208000000722 Akinetic Mutism Diseases 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
108010002913 Asialoglycoproteins Proteins 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
208000009017 Athetosis Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
108020004394 Complementary RNA Proteins 0.000 description 2
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
206010013496 Disturbance in attention Diseases 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
208000032274 Encephalopathy Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
206010063006 Facial spasm Diseases 0.000 description 2
208000004262 Food Hypersensitivity Diseases 0.000 description 2
206010016946 Food allergy Diseases 0.000 description 2
102000001267 GSK3 Human genes 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
206010020850 Hyperthyroidism Diseases 0.000 description 2
206010021133 Hypoventilation Diseases 0.000 description 2
MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
208000015592 Involuntary movements Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
201000000251 Locked-in syndrome Diseases 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
208000008238 Muscle Spasticity Diseases 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
108020004711 Nucleic Acid Probes Proteins 0.000 description 2
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000006199 Parasomnias Diseases 0.000 description 2
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
206010034719 Personality change Diseases 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
201000009916 Postpartum depression Diseases 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
206010037213 Psychomotor retardation Diseases 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
208000006289 Rett Syndrome Diseases 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
208000000323 Tourette Syndrome Diseases 0.000 description 2
208000016620 Tourette disease Diseases 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
229940123445 Tricyclic antidepressant Drugs 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
201000004810 Vascular dementia Diseases 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
208000018839 Wilson disease Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000013019 agitation Methods 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
208000020466 alteration of consciousness Diseases 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
230000000049 anti-anxiety effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000000164 antipsychotic agent Substances 0.000 description 2
229940005529 antipsychotics Drugs 0.000 description 2
229940005530 anxiolytics Drugs 0.000 description 2
230000004596 appetite loss Effects 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000000468 autoproteolytic effect Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
208000028683 bipolar I disease Diseases 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
238000007675 cardiac surgery Methods 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
208000014486 central sleep apnea syndrome Diseases 0.000 description 2
238000010382 chemical cross-linking Methods 0.000 description 2
229960004782 chlordiazepoxide Drugs 0.000 description 2
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
201000009950 chronic meningitis Diseases 0.000 description 2
WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000009850 completed effect Effects 0.000 description 2
238000007596 consolidation process Methods 0.000 description 2
125000000392 cycloalkenyl group Chemical group 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
201000001098 delayed sleep phase syndrome Diseases 0.000 description 2
208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 2
229960003914 desipramine Drugs 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000035622 drinking Effects 0.000 description 2
239000000975 dye Substances 0.000 description 2
235000005686 eating Nutrition 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229960004038 fluvoxamine Drugs 0.000 description 2
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
235000020932 food allergy Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000000799 fusogenic effect Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000007614 genetic variation Effects 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
208000008675 hereditary spastic paraplegia Diseases 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000000147 hypnotic effect Effects 0.000 description 2
150000003949 imides Chemical class 0.000 description 2
229960004801 imipramine Drugs 0.000 description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
229960004333 indeloxazine Drugs 0.000 description 2
230000007574 infarction Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000001788 irregular Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
208000019017 loss of appetite Diseases 0.000 description 2
235000021266 loss of appetite Nutrition 0.000 description 2
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000002483 medication Methods 0.000 description 2
210000004779 membrane envelope Anatomy 0.000 description 2
230000005056 memory consolidation Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
230000036651 mood Effects 0.000 description 2
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
201000003631 narcolepsy Diseases 0.000 description 2
239000013642 negative control Substances 0.000 description 2
210000000478 neocortex Anatomy 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
230000004031 neuronal differentiation Effects 0.000 description 2
230000006576 neuronal survival Effects 0.000 description 2
239000003900 neurotrophic factor Substances 0.000 description 2
229960001073 nomifensine Drugs 0.000 description 2
XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 2
125000005151 nonafluorobutanesulfonyl group Chemical group FC(C(C(S(=O)(=O)*)(F)F)(F)F)(C(F)(F)F)F 0.000 description 2
239000002853 nucleic acid probe Substances 0.000 description 2
208000001797 obstructive sleep apnea Diseases 0.000 description 2
229960005290 opipramol Drugs 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
229960002296 paroxetine Drugs 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 2
YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
150000003053 piperidines Chemical class 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000003518 presynaptic effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
150000004040 pyrrolidinones Chemical class 0.000 description 2
150000003252 quinoxalines Chemical class 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000011669 selenium Substances 0.000 description 2
229960002073 sertraline Drugs 0.000 description 2
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
208000018198 spasticity Diseases 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
230000002739 subcortical effect Effects 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
229960004940 sulpiride Drugs 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
208000006379 syphilis Diseases 0.000 description 2
150000003505 terpenes Chemical class 0.000 description 2
210000001103 thalamus Anatomy 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
150000003573 thiols Chemical group 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
230000032258 transport Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
239000003029 tricyclic antidepressant agent Substances 0.000 description 2
229960004799 tryptophan Drugs 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
239000004474 valine Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
TXSARNVUDNBDKR-GJMOJQLCSA-N (1r,4s,5r)-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylic acid Chemical compound C1C[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C TXSARNVUDNBDKR-GJMOJQLCSA-N 0.000 description 1
NGXDNMNOQDVTRL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(4-azido-2-nitroanilino)hexanoate Chemical compound [O-][N+](=O)C1=CC(N=[N+]=[N-])=CC=C1NCCCCCC(=O)ON1C(=O)CCC1=O NGXDNMNOQDVTRL-UHFFFAOYSA-N 0.000 description 1
QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
KRVOJOCLBAAKSJ-RDTXWAMCSA-N (2R,3R)-nemonapride Chemical compound C1=C(Cl)C(NC)=CC(OC)=C1C(=O)N[C@H]1[C@@H](C)N(CC=2C=CC=CC=2)CC1 KRVOJOCLBAAKSJ-RDTXWAMCSA-N 0.000 description 1
YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
UGSLDMJXBQKDCT-SDDRHHMPSA-N (2s)-5-oxo-n-[(1r,2s)-2-phenylcyclopropyl]pyrrolidine-2-carboxamide Chemical compound C1([C@@H]2C[C@H]2NC(=O)[C@H]2NC(=O)CC2)=CC=CC=C1 UGSLDMJXBQKDCT-SDDRHHMPSA-N 0.000 description 1
OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 description 1
FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
LOJCUYCKDGYLJH-UHFFFAOYSA-N 1-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN1CCNCC1 LOJCUYCKDGYLJH-UHFFFAOYSA-N 0.000 description 1
OZIZEXQRIOURIJ-UHFFFAOYSA-N 1-(4-benzoylphenyl)pyrrole-2,5-dione Chemical compound C=1C=C(N2C(C=CC2=O)=O)C=CC=1C(=O)C1=CC=CC=C1 OZIZEXQRIOURIJ-UHFFFAOYSA-N 0.000 description 1
BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 description 1
MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 description 1
KSQCNASWXSCJTD-UHFFFAOYSA-N 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(3,4,5-trimethoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C=C(OC)C(OC)=C(OC)C=2)CC1 KSQCNASWXSCJTD-UHFFFAOYSA-N 0.000 description 1
JQJNRLOLSDAAPI-UHFFFAOYSA-N 1-[4-[6-(dimethylamino)-1-benzofuran-2-yl]phenyl]pyrrole-2,5-dione Chemical compound O1C2=CC(N(C)C)=CC=C2C=C1C(C=C1)=CC=C1N1C(=O)C=CC1=O JQJNRLOLSDAAPI-UHFFFAOYSA-N 0.000 description 1
RGNHAWFQWRAADF-UHFFFAOYSA-N 1-[4-[[4-(dimethylamino)phenyl]diazenyl]phenyl]pyrrole-2,5-dione Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N2C(C=CC2=O)=O)C=C1 RGNHAWFQWRAADF-UHFFFAOYSA-N 0.000 description 1
CTTVWDKXMPBZMQ-UHFFFAOYSA-N 1-[6-(dimethylamino)naphthalen-2-yl]undecan-1-one Chemical compound CCCCCCCCCCC(=O)c1ccc2cc(ccc2c1)N(C)C CTTVWDKXMPBZMQ-UHFFFAOYSA-N 0.000 description 1
MKRYCGYWVOMYPS-UHFFFAOYSA-N 1-dodecyl-2-[3-(1-dodecyl-3,3-dimethylindol-1-ium-2-yl)prop-2-enylidene]-3,3-dimethylindole Chemical compound CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCC)C1=CC=CC1=[N+](CCCCCCCCCCCC)C2=CC=CC=C2C1(C)C MKRYCGYWVOMYPS-UHFFFAOYSA-N 0.000 description 1
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 1
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 1
YRJDKKPCZVIYHO-UHFFFAOYSA-N 3-[4-[2-(2,5-dimethoxyphenyl)ethenyl]phenyl]pyrrole-2,5-dione Chemical compound COC1=CC=C(OC)C(C=CC=2C=CC(=CC=2)C=2C(NC(=O)C=2)=O)=C1 YRJDKKPCZVIYHO-UHFFFAOYSA-N 0.000 description 1
XNYADQAHHJHQJA-UHFFFAOYSA-N 3-pyren-1-ylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=C4C=CC=C5C=CC(C3=C54)=CC=2)=C1 XNYADQAHHJHQJA-UHFFFAOYSA-N 0.000 description 1
PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
LMEHJKJEPRYEEB-UHFFFAOYSA-N 5-prop-1-ynylpyrimidine Chemical compound CC#CC1=CN=CN=C1 LMEHJKJEPRYEEB-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
206010001423 Advanced sleep phase Diseases 0.000 description 1
208000017194 Affective disease Diseases 0.000 description 1
101710092462 Alpha-hemolysin Proteins 0.000 description 1
101710197219 Alpha-toxin Proteins 0.000 description 1
102100034452 Alternative prion protein Human genes 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101800001415 Bri23 peptide Proteins 0.000 description 1
RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
101800000655 C-terminal peptide Proteins 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
101100522123 Caenorhabditis elegans ptc-1 gene Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
102000005403 Casein Kinases Human genes 0.000 description 1
108010031425 Casein Kinases Proteins 0.000 description 1
108050004290 Cecropin Proteins 0.000 description 1
206010008096 Cerebral atrophy Diseases 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
206010061764 Chromosomal deletion Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
244000276331 Citrus maxima Species 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
241000766026 Coregonus nasus Species 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
206010012218 Delirium Diseases 0.000 description 1
206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
108700029231 Developmental Genes Proteins 0.000 description 1
208000012239 Developmental disease Diseases 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010049119 Emotional distress Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
WMFSSTNVXWNLKI-UHFFFAOYSA-N Flutazolam Chemical compound O1CCN2CC(=O)N(CCO)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1F WMFSSTNVXWNLKI-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
206010060891 General symptom Diseases 0.000 description 1
208000011688 Generalised anxiety disease Diseases 0.000 description 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010026389 Gramicidin Proteins 0.000 description 1
206010018671 Grandiosity Diseases 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
101150039660 HA gene Proteins 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
238000012450 HuMAb Mouse Methods 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
206010021034 Hypometabolism Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
208000001456 Jet Lag Syndrome Diseases 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000009829 Lewy Body Disease Diseases 0.000 description 1
108060003100 Magainin Proteins 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
102100025169 Max-binding protein MNT Human genes 0.000 description 1
ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
108010036176 Melitten Proteins 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
208000019430 Motor disease Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101001055252 Mus musculus Indian hedgehog protein Proteins 0.000 description 1
101000616468 Mus musculus Sonic hedgehog protein Proteins 0.000 description 1
208000007379 Muscle Hypotonia Diseases 0.000 description 1
206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
XQVWYOYUZDUNRW-UHFFFAOYSA-N N-Phenyl-1-naphthylamine Chemical compound C=1C=CC2=CC=CC=C2C=1NC1=CC=CC=C1 XQVWYOYUZDUNRW-UHFFFAOYSA-N 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
241001057495 Neda Species 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108090000556 Neuregulin-1 Proteins 0.000 description 1
102400000058 Neuregulin-1 Human genes 0.000 description 1
102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
239000007990 PIPES buffer Substances 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241000051107 Paraechinus aethiopicus Species 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
206010034057 Partial complex seizures Diseases 0.000 description 1
208000002141 Pellagra Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
208000012202 Pervasive developmental disease Diseases 0.000 description 1
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
CAMYKONBWHRPDD-UHFFFAOYSA-N Phenprobamate Chemical compound NC(=O)OCCCC1=CC=CC=C1 CAMYKONBWHRPDD-UHFFFAOYSA-N 0.000 description 1
101710124951 Phospholipase C Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
WBTCZXYOKNRFQX-UHFFFAOYSA-N S1(=O)(=O)NC1=O Chemical compound S1(=O)(=O)NC1=O WBTCZXYOKNRFQX-UHFFFAOYSA-N 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
206010040026 Sensory disturbance Diseases 0.000 description 1
206010040030 Sensory loss Diseases 0.000 description 1
108091027967 Small hairpin RNA Proteins 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
208000002667 Subdural Hematoma Diseases 0.000 description 1
206010048327 Supranuclear palsy Diseases 0.000 description 1
208000027522 Sydenham chorea Diseases 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
102100031013 Transgelin Human genes 0.000 description 1
208000005386 Transient Global Amnesia Diseases 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
229930003779 Vitamin B12 Natural products 0.000 description 1
238000012452 Xenomouse strains Methods 0.000 description 1
QICQDZXGZOVTEF-UHFFFAOYSA-N [3-(3,4-dichlorophenyl)-2,3-dihydro-1h-inden-1-yl]-methylazanium;chloride Chemical compound Cl.C12=CC=CC=C2C(NC)CC1C1=CC=C(Cl)C(Cl)=C1 QICQDZXGZOVTEF-UHFFFAOYSA-N 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
229960000276 acetophenazine Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
230000036982 action potential Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
208000012826 adjustment disease Diseases 0.000 description 1
CGNMLOKEMNBUAI-UHFFFAOYSA-N adrafinil Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)NO)C1=CC=CC=C1 CGNMLOKEMNBUAI-UHFFFAOYSA-N 0.000 description 1
229960002820 adrafinil Drugs 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
239000002776 alpha toxin Substances 0.000 description 1
229960004538 alprazolam Drugs 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
229960000959 amineptine Drugs 0.000 description 1
ONNOFKFOZAJDHT-UHFFFAOYSA-N amineptine Chemical compound C1CC2=CC=CC=C2C(NCCCCCCC(=O)O)C2=CC=CC=C21 ONNOFKFOZAJDHT-UHFFFAOYSA-N 0.000 description 1
125000005021 aminoalkenyl group Chemical group 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
125000005014 aminoalkynyl group Chemical group 0.000 description 1
229960003036 amisulpride Drugs 0.000 description 1
NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
229960002519 amoxapine Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
229960004372 aripiprazole Drugs 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
208000029560 autism spectrum disease Diseases 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
235000021167 banquet Nutrition 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
BEWNZPMDJIGBED-UHFFFAOYSA-N benmoxin Chemical compound C=1C=CC=CC=1C(C)NNC(=O)C1=CC=CC=C1 BEWNZPMDJIGBED-UHFFFAOYSA-N 0.000 description 1
229950011271 benmoxin Drugs 0.000 description 1
229960002507 benperidol Drugs 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
GNRXCIONJWKSEA-UHFFFAOYSA-N benzoctamine Chemical compound C12=CC=CC=C2C2(CNC)C3=CC=CC=C3C1CC2 GNRXCIONJWKSEA-UHFFFAOYSA-N 0.000 description 1
229960001303 benzoctamine Drugs 0.000 description 1
229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000008827 biological function Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
208000022257 bipolar II disease Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
229960004037 bromperidol Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
229960001058 bupropion Drugs 0.000 description 1
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
229950009824 buramate Drugs 0.000 description 1
YFLRYAVDPKONNX-UHFFFAOYSA-N buramate Chemical compound OCCOC(=O)NCC1=CC=CC=C1 YFLRYAVDPKONNX-UHFFFAOYSA-N 0.000 description 1
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000011111 cardboard Substances 0.000 description 1
XZSMZRXAEFNJCU-UHFFFAOYSA-N carfenazine Chemical compound C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 XZSMZRXAEFNJCU-UHFFFAOYSA-N 0.000 description 1
229950009852 carfenazine Drugs 0.000 description 1
KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 description 1
229950006044 caroxazone Drugs 0.000 description 1
NWPJLRSCSQHPJV-UHFFFAOYSA-N carpipramine Chemical compound C1CN(CCCN2C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 NWPJLRSCSQHPJV-UHFFFAOYSA-N 0.000 description 1
229960000700 carpipramine Drugs 0.000 description 1
230000022159 cartilage development Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
210000002932 cholinergic neuron Anatomy 0.000 description 1
208000012601 choreatic disease Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
230000037326 chronic stress Effects 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
QAZKXHSIKKNOHH-UHFFFAOYSA-N clocapramine Chemical compound C1CN(CCCN2C3=CC(Cl)=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 QAZKXHSIKKNOHH-UHFFFAOYSA-N 0.000 description 1
229950001534 clocapramine Drugs 0.000 description 1
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
229960003120 clonazepam Drugs 0.000 description 1
229960001184 clopenthixol Drugs 0.000 description 1
229960004362 clorazepate Drugs 0.000 description 1
XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
230000003930 cognitive ability Effects 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
101150118300 cos gene Proteins 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
229920006237 degradable polymer Polymers 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
SEDQWOMFMIJKCU-UHFFFAOYSA-N demexiptiline Chemical compound C1=CC2=CC=CC=C2C(=NOCCNC)C2=CC=CC=C21 SEDQWOMFMIJKCU-UHFFFAOYSA-N 0.000 description 1
229950010189 demexiptiline Drugs 0.000 description 1
210000001947 dentate gyrus Anatomy 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
HGKAMARNFGKMLC-RBUKOAKNSA-N dexoxadrol Chemical compound C([C@H]1[C@@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-RBUKOAKNSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
230000029087 digestion Effects 0.000 description 1
LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
229950006161 dioxadrol Drugs 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
208000018459 dissociative disease Diseases 0.000 description 1
230000009429 distress Effects 0.000 description 1
125000000976 dodecenoyl group Chemical group C(C=CCCCCCCCCC)(=O)* 0.000 description 1
229960000394 droperidol Drugs 0.000 description 1
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002898 effect on depression Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
230000004970 emotional disturbance Effects 0.000 description 1
229950010052 enciprazine Drugs 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
201000003104 endogenous depression Diseases 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000010326 executive functioning Effects 0.000 description 1
229960005182 febarbamate Drugs 0.000 description 1
QHZQILHUJDRDAI-UHFFFAOYSA-N febarbamate Chemical compound O=C1N(CC(COCCCC)OC(N)=O)C(=O)NC(=O)C1(CC)C1=CC=CC=C1 QHZQILHUJDRDAI-UHFFFAOYSA-N 0.000 description 1
PDTADBTVZXKSJM-UHFFFAOYSA-N fencamine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1NCCN(C)C(C)CC1=CC=CC=C1 PDTADBTVZXKSJM-UHFFFAOYSA-N 0.000 description 1
SNJDSTGQYRTZJT-UHFFFAOYSA-N fenpentadiol Chemical compound CC(C)(O)CC(C)(O)C1=CC=C(Cl)C=C1 SNJDSTGQYRTZJT-UHFFFAOYSA-N 0.000 description 1
229950011196 fenpentadiol Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical compound C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 description 1
229950003678 flesinoxan Drugs 0.000 description 1
229960002419 flupentixol Drugs 0.000 description 1
229960002690 fluphenazine Drugs 0.000 description 1
229950009354 flutazolam Drugs 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
210000001222 gaba-ergic neuron Anatomy 0.000 description 1
230000005021 gait Effects 0.000 description 1
DASHZBBQOARCMQ-QPJJXVBHSA-N gbr-13069 Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(C\C=C\C=2C=CC=CC=2)CC1 DASHZBBQOARCMQ-QPJJXVBHSA-N 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
208000029364 generalized anxiety disease Diseases 0.000 description 1
238000012248 genetic selection Methods 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
IUAYMJGZBVDSGL-XNNAEKOYSA-N gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
229950009774 gramicidin s Drugs 0.000 description 1
229940027804 halcion Drugs 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
229960003569 hematoporphyrin Drugs 0.000 description 1
206010019465 hemiparesis Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
229960000930 hydroxyzine Drugs 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
229950002473 indalpine Drugs 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000035992 intercellular communication Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
238000009533 lab test Methods 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000011977 language disease Diseases 0.000 description 1
230000007653 larval development Effects 0.000 description 1
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000003723 learning disability Diseases 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
BKPLVPRTTWIDNL-ZIAGYGMSSA-N levofacetoperane Chemical compound C([C@@H]1[C@H](OC(=O)C)C=2C=CC=CC=2)CCCN1 BKPLVPRTTWIDNL-ZIAGYGMSSA-N 0.000 description 1
229950004771 levofacetoperane Drugs 0.000 description 1
QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
239000000865 liniment Substances 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
238000009593 lumbar puncture Methods 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036244 malformation Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
229960004090 maprotiline Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229960000299 mazindol Drugs 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
BULMIDNYAWYAMZ-UHFFFAOYSA-N mecloralurea Chemical compound CNC(=O)NC(O)C(Cl)(Cl)Cl BULMIDNYAWYAMZ-UHFFFAOYSA-N 0.000 description 1
229950007642 mecloralurea Drugs 0.000 description 1
VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004630 mental health Effects 0.000 description 1
ZMNSRFNUONFLSP-UHFFFAOYSA-N mephenoxalone Chemical compound COC1=CC=CC=C1OCC1OC(=O)NC1 ZMNSRFNUONFLSP-UHFFFAOYSA-N 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
YXVZOBVWVRFPTE-UHFFFAOYSA-N metapramine Chemical compound CNC1CC2=CC=CC=C2N(C)C2=CC=CC=C12 YXVZOBVWVRFPTE-UHFFFAOYSA-N 0.000 description 1
229950006180 metapramine Drugs 0.000 description 1
WLUHMAZNVINQRC-UHFFFAOYSA-M methanesulfonate;1-[2-[4-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]pyridin-1-ium-1-yl]ethyl]pyrrole-2,5-dione Chemical compound CS([O-])(=O)=O.C1=CC(OC)=CC=C1C1=CN=C(C=2C=C[N+](CCN3C(C=CC3=O)=O)=CC=2)O1 WLUHMAZNVINQRC-UHFFFAOYSA-M 0.000 description 1
AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
ANUCDXCTICZJRH-UHFFFAOYSA-N mexazolam Chemical compound C=1C=C(Cl)C=C2C=1NC(=O)CN1C(C)COC21C1=CC=CC=C1Cl ANUCDXCTICZJRH-UHFFFAOYSA-N 0.000 description 1
229950000412 mexazolam Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
229960000600 milnacipran Drugs 0.000 description 1
229960004758 minaprine Drugs 0.000 description 1
LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 1
YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
229960004644 moclobemide Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000003990 molecular pathway Effects 0.000 description 1
AGAHNABIDCTLHW-UHFFFAOYSA-N moperone Chemical compound C1=CC(C)=CC=C1C1(O)CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 AGAHNABIDCTLHW-UHFFFAOYSA-N 0.000 description 1
229960000758 moperone Drugs 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
210000000337 motor cortex Anatomy 0.000 description 1
230000007659 motor function Effects 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
229950011108 nemonapride Drugs 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
230000007372 neural signaling Effects 0.000 description 1
208000011851 neurological alteration Diseases 0.000 description 1
231100000878 neurological injury Toxicity 0.000 description 1
230000003227 neuromodulating effect Effects 0.000 description 1
230000017511 neuron migration Effects 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
230000003557 neuropsychological effect Effects 0.000 description 1
238000010855 neuropsychological testing Methods 0.000 description 1
208000002040 neurosyphilis Diseases 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
229960002640 nordazepam Drugs 0.000 description 1
201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
FODQIVGFADUBKE-UHFFFAOYSA-N octamoxin Chemical compound CCCCCCC(C)NN FODQIVGFADUBKE-UHFFFAOYSA-N 0.000 description 1
229950006863 octamoxin Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
229960005017 olanzapine Drugs 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
230000005305 organ development Effects 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000011164 ossification Effects 0.000 description 1
229940053544 other antidepressants in atc Drugs 0.000 description 1
229940054010 other antipsychotics in atc Drugs 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
WBLPIVIXQOFTPQ-UHFFFAOYSA-N oxanamide Chemical compound CCCC1OC1(CC)C(N)=O WBLPIVIXQOFTPQ-UHFFFAOYSA-N 0.000 description 1
229950005413 oxanamide Drugs 0.000 description 1
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
229960004535 oxazepam Drugs 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
WAFIYOULDIWAKR-UHFFFAOYSA-N oxyfenamate Chemical compound NC(=O)OCC(O)(CC)C1=CC=CC=C1 WAFIYOULDIWAKR-UHFFFAOYSA-N 0.000 description 1
229950005405 oxyfenamate Drugs 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
239000000123 paper Substances 0.000 description 1
239000011087 paperboard Substances 0.000 description 1
210000002990 parathyroid gland Anatomy 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
210000001152 parietal lobe Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960004505 penfluridol Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
230000008447 perception Effects 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
238000002823 phage display Methods 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
229960000964 phenelzine Drugs 0.000 description 1
229950000688 phenothiazine Drugs 0.000 description 1
GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
229960002572 phenprobamate Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical group NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
229960002776 pipamperone Drugs 0.000 description 1
229960004265 piperacetazine Drugs 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
229940068151 pipothiazine Drugs 0.000 description 1
JOMHSQGEWSNUKU-UHFFFAOYSA-N pipotiazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 JOMHSQGEWSNUKU-UHFFFAOYSA-N 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001987 poloxamine Polymers 0.000 description 1
229920000889 poly(m-phenylene isophthalamide) Polymers 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
210000002442 prefrontal cortex Anatomy 0.000 description 1
230000002360 prefrontal effect Effects 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000007639 printing Methods 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
108010056119 protease So Proteins 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229960002601 protriptyline Drugs 0.000 description 1
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000002213 purine nucleotide Substances 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003220 pyrenes Chemical class 0.000 description 1
239000002719 pyrimidine nucleotide Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
201000005439 recurrent hypersomnia Diseases 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
201000009570 retrograde amnesia Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
229960001534 risperidone Drugs 0.000 description 1
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
229950005741 rolipram Drugs 0.000 description 1
102220080600 rs797046116 Human genes 0.000 description 1
ZAQLTGAFVMGUMB-IFFAKLHKSA-N rti-121 Chemical compound C1([C@H]2CC3CC[C@@H](N3C)[C@H]2C(=O)OC(C)C)=CC=C(I)C=C1 ZAQLTGAFVMGUMB-IFFAKLHKSA-N 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
150000003346 selenoethers Chemical class 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
230000037152 sensory function Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
229940035004 seroquel Drugs 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
208000012201 sexual and gender identity disease Diseases 0.000 description 1
208000015891 sexual disease Diseases 0.000 description 1
230000006403 short-term memory Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
238000012868 site-directed mutagenesis technique Methods 0.000 description 1
230000037046 slow wave activity Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000002023 somite Anatomy 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
229950001675 spiperone Drugs 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
150000008053 sultones Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
210000002182 synaptic membrane Anatomy 0.000 description 1
230000003956 synaptic plasticity Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
IFLREYGFSNHWGE-UHFFFAOYSA-N tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 1
RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
150000003566 thiocarboxylic acids Chemical class 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
150000005075 thioxanthenes Chemical class 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
229960002309 toloxatone Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
231100000133 toxic exposure Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
108091006107 transcriptional repressors Proteins 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
229960003741 tranylcypromine Drugs 0.000 description 1
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 description 1
229960002341 trifluperidol Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
150000003813 tropane derivatives Chemical class 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1
PRBORDFJHHAISJ-UHFFFAOYSA-N tybamate Chemical compound CCCCNC(=O)OCC(C)(CCC)COC(N)=O PRBORDFJHHAISJ-UHFFFAOYSA-N 0.000 description 1
229960002560 tybamate Drugs 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
229940102566 valproate Drugs 0.000 description 1
NAUWTFJOPJWYOT-UHFFFAOYSA-N vanoxerine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(CCCC=2C=CC=CC=2)CC1 NAUWTFJOPJWYOT-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229960004688 venlafaxine Drugs 0.000 description 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
230000007497 verbal memory Effects 0.000 description 1
230000008189 vertebrate development Effects 0.000 description 1
229960001255 viloxazine Drugs 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1
208000002670 vitamin B12 deficiency Diseases 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1
230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
QUSLQENMLDRCTO-YJNKXOJESA-N win 35428 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(F)C=C1 QUSLQENMLDRCTO-YJNKXOJESA-N 0.000 description 1
230000003936 working memory Effects 0.000 description 1
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
229960000607 ziprasidone Drugs 0.000 description 1
WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1